Luxturna (voretigene neparvovec)
pCPA File Number:
21334
Negotiation Status:
Concluded with an LOI
Indication(s):
Vision loss, inherited retinal dystrophy
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
SG0643-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: